Last Updated: November 20, 2026

Zoster vaccine recombinant, adjuvanted - Biologic Drug Details

« Back to Dashboard


Summary for zoster vaccine recombinant, adjuvanted
Tradenames:1
High Confidence Patents:23
Applicants:1
BLAs:1
Suppliers: see list2
Recent Clinical Trials: See clinical trials for zoster vaccine recombinant, adjuvanted
Recent Clinical Trials for zoster vaccine recombinant, adjuvanted

Identify potential brand extensions & biosimilar entrants

SponsorPhase
GlaxoSmithKlinePhase 2
University of Colorado, DenverPhase 2
University of RochesterEarly Phase 1

See all zoster vaccine recombinant, adjuvanted clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for zoster vaccine recombinant, adjuvanted Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for zoster vaccine recombinant, adjuvanted Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Glaxosmithkline Biologicals SHINGRIX zoster vaccine recombinant, adjuvanted Injection 125614 ⤷  Start Trial 2035-09-16 DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals SHINGRIX zoster vaccine recombinant, adjuvanted Injection 125614 ⤷  Start Trial 2039-03-15 DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals SHINGRIX zoster vaccine recombinant, adjuvanted Injection 125614 ⤷  Start Trial 2037-07-06 DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals SHINGRIX zoster vaccine recombinant, adjuvanted Injection 125614 ⤷  Start Trial 2038-10-02 DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals SHINGRIX zoster vaccine recombinant, adjuvanted Injection 125614 ⤷  Start Trial 2038-07-25 DrugPatentWatch analysis and company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for zoster vaccine recombinant, adjuvanted Derived from Patent Text Search

These patents were obtained by searching patent claims

Shingrix Market Dynamics, Financial Trajectory, Exclusivity and Competitive Risk

Last updated: September 24, 2026

GSK’s Shingrix, the branded version of zoster vaccine recombinant, adjuvanted, is the leading adult shingles vaccine globally. Its market position rests on high efficacy, broad U.S. recommendations, the withdrawal of Merck’s Zostavax from the U.S. market, and a two-dose schedule that creates recurring demand from newly eligible adults. Shingrix sales rose from approximately £2.0 billion in 2020 to about £4.3 billion in 2024, making it one of GSK’s most important growth products.[1]

The commercial outlook remains positive but is shifting from rapid U.S. launch and catch-up demand toward international expansion, routine adult vaccination and replacement demand. Long-term erosion risk is more likely to come from new vaccine platforms, price pressure and market saturation than from a conventional generic or biosimilar launch.

What is zoster vaccine recombinant, adjuvanted?

Zoster vaccine recombinant, adjuvanted is a non-live vaccine containing recombinant varicella-zoster virus glycoprotein E and GSK’s AS01B adjuvant system. It is marketed as Shingrix.

The vaccine is administered as a two-dose intramuscular series. The second dose is generally given two to six months after the first dose, although immunocompromised adults may receive the second dose one to two months after the initial dose.[2]

FDA-approved indications

The U.S. Food and Drug Administration approved Shingrix in October 2017 for the prevention of herpes zoster in adults aged 50 years and older. The FDA later expanded the indication to adults aged 18 years and older who are or will be immunodeficient or immunosuppressed because of disease or therapy.[3]

The CDC recommends Shingrix for:

  • Adults aged 50 years and older.
  • Adults aged 19 years and older who are immunocompromised or immunosuppressed.
  • Adults who previously received Zostavax.
  • Adults with a prior history of shingles.

Shingrix is not a live vaccine. That distinction supports its use in many immunocompromised populations for whom a live attenuated vaccine is unsuitable.

How has the Shingrix market developed?

Shingrix benefited from three structural market conditions:

  1. A large population of adults at risk of herpes zoster.
  2. Strong efficacy relative to the prior live vaccine.
  3. The U.S. withdrawal of Zostavax.

Merck discontinued Zostavax in the United States in November 2020. The product remained available in some international markets for a period, but it no longer provided meaningful U.S. competition.[4]

Clinical-trial data showed vaccine efficacy above 90% across older adult age groups, including adults aged 70 years and older. Protection also remained high during follow-up, supporting physician and payer adoption.[5]

Key market drivers

The strongest demand drivers are:

  • Aging populations in the United States, Europe and Japan.
  • Increased awareness of postherpetic neuralgia and shingles complications.
  • Expanded vaccination recommendations for immunocompromised adults.
  • Pharmacy-based adult immunization.
  • Government reimbursement and national immunization programs.
  • Completion of partially vaccinated two-dose patients.

The two-dose schedule increases doses per fully vaccinated patient but also creates drop-off risk between the first and second injections. GSK and pharmacy channels have benefited from the ability to administer adult vaccines outside traditional primary-care settings.

What is the financial trajectory for Shingrix?

Shingrix has grown from a launch-stage vaccine into a multibillion-pound product. Reported sales are affected by foreign-exchange movements, U.S. public-sector purchasing, international tender timing and the pace of vaccination in older adults.

Fiscal year Approximate Shingrix sales Commercial development
2018 £784 million First full year after U.S. launch
2019 £1.8 billion Rapid U.S. uptake and supply expansion
2020 £2.0 billion COVID-19 disruption offset by established demand
2021 £1.7 billion Adult vaccination disruptions and supply effects
2022 £2.96 billion Strong U.S. recovery and international growth
2023 £3.45 billion Continued U.S. demand and broader global uptake
2024 Approximately £4.3 billion Further growth, led by U.S. and international markets

Sources: GSK annual reports and full-year results.[1,6]

Shingrix has become a major contributor to GSK’s vaccine segment and group revenue. It also has favorable strategic economics because the product is differentiated, physician awareness is high and the U.S. market lacks a directly competing marketed shingles vaccine.

What could slow revenue growth?

The product’s growth rate is likely to moderate as the initial U.S. catch-up population becomes more vaccinated. The main risks are:

  • Lower annual incidence of first-dose patients after broad adult coverage.
  • Delayed second doses.
  • Reduced discretionary spending or lower pharmacy traffic.
  • Public-payer price negotiations and tender pressure.
  • Manufacturing constraints or temporary supply imbalance.
  • Competition from future recombinant or next-generation shingles vaccines.
  • International reimbursement differences.

A mature-market plateau would not imply immediate revenue collapse. Shingrix can continue generating recurring demand from people reaching age 50, immunocompromised patients, incomplete vaccination courses and countries expanding recommendations.

What patents protect Shingrix?

Shingrix is protected by a portfolio covering the recombinant glycoprotein E antigen, AS01 adjuvant technology, vaccine compositions, antigen-adjuvant combinations, immunization methods and manufacturing processes.

The relevant intellectual-property categories include:

IP category Commercial relevance
Glycoprotein E antigen constructs Protects the recombinant antigen used in the vaccine
AS01 adjuvant technology Covers adjuvant components and combinations
Vaccine composition claims Protects antigen-adjuvant formulations
Method-of-use claims Covers prevention of herpes zoster and related conditions
Manufacturing claims Protects expression, purification, formulation and fill-finish processes
Combination and dosing claims May cover two-dose schedules and immunization populations

GSK’s vaccine technology originated in part from its broader AS01 adjuvant platform and earlier development programs involving the U.S. government and academic partners. Patent rights vary by jurisdiction and by patent family. A single expiry date does not describe the entire Shingrix estate.

When does Shingrix lose exclusivity?

Shingrix does not have one publicly controlling exclusivity expiration date comparable to a small-molecule product with a single Orange Book-listed patent. Its protection is distributed across biologic regulatory exclusivity, composition patents, adjuvant patents, formulation claims and manufacturing know-how.

The U.S. biologic reference product was approved in 2017. The statutory data-exclusivity period for a reference biological product approved under the Public Health Service Act is 12 years, subject to the operation of the applicable statutory framework. That period does not by itself prevent an independently developed competing vaccine from seeking approval through a full biologics application.

The commercially important protection is therefore likely to extend beyond regulatory data exclusivity through a combination of patent rights and manufacturing barriers. Patent term can also be affected by patent-term adjustment, terminal disclaimers, priority claims and jurisdiction-specific prosecution.

What is the Orange Book status of Shingrix?

Shingrix is not an Orange Book-listed drug in the conventional small-molecule sense. FDA-approved biologic products are primarily tracked through the Purple Book rather than the Orange Book.[7]

As a result:

  • Shingrix does not have a conventional Orange Book patent-listing strategy.
  • A generic applicant cannot use the ordinary ANDA Paragraph IV pathway to substitute for Shingrix.
  • Patent certifications under Hatch-Waxman do not provide the standard route for challenging Shingrix.
  • Any competing biologic or vaccine product would require an applicable biologics approval pathway.

Are there Paragraph IV challenges to Shingrix?

There is no conventional Paragraph IV challenge framework for Shingrix because the product is a biologic vaccine rather than an Orange Book-listed small-molecule drug.

A competitor seeking to market a similar shingles vaccine would likely need to pursue an independent biologics application under section 351(a) of the Public Health Service Act. The standard biosimilar pathway is not a practical substitute for conventional vaccine development because a competing shingles vaccine would generally need to establish its own antigen, adjuvant, manufacturing controls, clinical performance and safety profile.

No major public U.S. Paragraph IV litigation has defined the Shingrix market in the manner seen with major small-molecule drugs.

Is Shingrix exposed to biosimilar competition?

Shingrix faces limited near-term biosimilar risk. A biosimilar is highly similar to a reference biological product, with no clinically meaningful differences in safety, purity and potency. Shingrix includes a proprietary recombinant antigen and a complex adjuvant system. Demonstrating similarity for the full product, including the antigen-adjuvant interaction and immune response, would be more difficult than copying a conventional small molecule.

A future competitor could instead develop a new shingles vaccine under a full biologics application. That route would require substantial clinical and manufacturing investment. The likely competitive threat is a differentiated vaccine with comparable efficacy, fewer doses, lower reactogenicity or a lower price, rather than an interchangeable Shingrix copy.

What formulation and manufacturing barriers protect Shingrix?

The principal technical barriers are the integration of recombinant glycoprotein E with AS01B, control of antigen quality, adjuvant consistency, stability, sterile manufacturing and the two-component presentation of the product.

Shingrix’s commercial product is supplied as two separate components that are reconstituted before administration. Manufacturing must control:

  • Antigen expression and purification.
  • Adjuvant component quality.
  • Particle and emulsion characteristics.
  • Potency and identity assays.
  • Sterility and stability.
  • Cold-chain handling.
  • Consistent dose preparation.

These controls raise entry costs even if a competitor can reproduce the broad scientific concept. Vaccine manufacturing capacity is also a strategic barrier. A new entrant would need validated facilities, regulatory inspections, commercial-scale supply and distribution through pharmacies, physicians and government procurement channels.

What is the competitive landscape for shingles vaccines?

Product Developer Current U.S. position Competitive status
Shingrix GSK Marketed and recommended Dominant U.S. product
Zostavax Merck Discontinued in U.S. in 2020 No meaningful current U.S. supply
Future recombinant vaccines Potential new entrants Not established Main long-term threat

Shingrix has no active U.S. direct competitor with an equivalent commercial position. International markets can have different vaccine availability, reimbursement rules and public-health recommendations.

The strongest future competitor would likely need to offer one or more of the following:

  • A one-dose schedule.
  • Lower rates of injection-site reactions.
  • Lower procurement cost.
  • Easier storage.
  • Strong efficacy in older and immunocompromised populations.
  • Improved protection durability.
  • Broader combination use with other adult vaccines.

What patent litigation and licensing issues affect Shingrix?

Publicly visible Shingrix risk has been lower than the litigation risk surrounding many high-value small-molecule products. There is no established Paragraph IV litigation pattern, and the product has not faced a major U.S. generic-substitution campaign.

The principal legal issues are more likely to involve:

  • Ownership and licensing of AS01-related adjuvant technology.
  • Government or institutional rights arising from vaccine research funding.
  • Patent disputes over glycoprotein E constructs or adjuvant combinations.
  • Manufacturing process patents.
  • Contract manufacturing and supply arrangements.
  • Foreign patent prosecution and opposition proceedings.

GSK’s commercial position also reflects a broader technology base rather than one patent. That reduces the risk that the loss of one claim would immediately eliminate the product’s market protection.

How strong is the Shingrix patent estate?

The Shingrix patent estate is commercially strong but not impenetrable. Its strengths are product complexity, platform technology, manufacturing know-how, high clinical-performance requirements and the absence of an approved interchangeable competitor.

Its limitations are:

  • The earliest core patents began filing well before the 2017 FDA approval.
  • Patent terms are finite.
  • Some broad vaccine concepts may face validity or written-description challenges.
  • A competitor can design around individual composition claims.
  • A new entrant could pursue a full 351(a) approval without infringing every Shingrix claim.

Overall, the market barrier is stronger than the patent estate alone. Regulatory, clinical, manufacturing and channel barriers work together.

What generic launch scenarios exist for Shingrix?

Base case

GSK maintains U.S. leadership through the late 2020s, while annual growth slows as the initial eligible population becomes more vaccinated. International markets and recurring age-based demand offset part of the U.S. moderation.

Downside case

A competing vaccine or pricing pressure reduces public-sector and pharmacy margins. Lower first-dose demand and poor second-dose completion reduce volume growth before patent rights expire.

Disruption case

A one-dose vaccine with comparable efficacy and better tolerability gains approval. GSK would face accelerated switching, formulary pressure and potentially lower prices even if Shingrix remains clinically effective.

A conventional generic launch is unlikely to be the primary erosion mechanism. The more realistic risk is a new full-approval vaccine competing on clinical convenience, price or tolerability.

What is the FDA regulatory status of Shingrix?

Shingrix is FDA-approved as a recombinant, adjuvanted zoster vaccine. It is regulated as a biologic under the Public Health Service Act and is listed in the FDA’s biologics reference-product framework rather than treated as an ordinary Orange Book small molecule.[3,7]

The product’s label includes warnings concerning severe allergic reactions and common local or systemic adverse reactions. The most frequent reactions include injection-site pain, myalgia, fatigue, headache, shivering, fever and gastrointestinal symptoms.[2]

Key Takeaways

  • Shingrix is GSK’s leading adult vaccine and generated approximately £4.3 billion in sales in 2024.
  • The U.S. market has no meaningful direct commercial competitor after Merck discontinued Zostavax.
  • Revenue should remain durable but growth is likely to moderate as catch-up vaccination declines.
  • Shingrix is not exposed to the ordinary Orange Book Paragraph IV generic pathway.
  • Its protection combines patents, biologic exclusivity, manufacturing know-how, clinical data and supply infrastructure.
  • Biosimilar risk is limited; the more credible threat is a new vaccine approved through a full biologics application.
  • The most important commercial risks are market saturation, public-payer pricing, supply execution and a future one-dose or better-tolerated vaccine.

FAQs

Is Shingrix a biologic drug or a vaccine?

Shingrix is a recombinant biologic vaccine. It contains recombinant varicella-zoster virus glycoprotein E and the AS01B adjuvant system.

Does Shingrix have an Orange Book patent expiration date?

No conventional Orange Book expiration date governs Shingrix. The product is a biologic vaccine tracked primarily through the Purple Book and protected by multiple patent and regulatory rights.

Can a generic manufacturer copy Shingrix?

A conventional generic manufacturer cannot use the ordinary ANDA route to copy Shingrix. A competing manufacturer would generally need to develop and obtain approval for a biologic vaccine through an applicable biologics pathway.

What is the biggest commercial risk to Shingrix?

The largest long-term risk is a competing vaccine with similar efficacy but a one-dose schedule, lower reactogenicity or a lower price. Near-term risks include U.S. market saturation and reimbursement pressure.

Why is Shingrix financially important to GSK?

Shingrix is one of GSK’s largest growth products, with annual sales exceeding £4 billion. It supports GSK’s vaccines portfolio and offsets slower growth in mature pharmaceutical products.

References

  1. GSK plc. (2025). Annual report 2024. London, United Kingdom: GSK plc.
  2. U.S. Food and Drug Administration. (2024). Shingrix prescribing information. Silver Spring, MD: FDA.
  3. U.S. Food and Drug Administration. (2017). FDA approves new vaccine to prevent shingles in adults. Silver Spring, MD: FDA.
  4. Merck & Co., Inc. (2020). Merck to discontinue Zostavax in the United States. Kenilworth, NJ: Merck.
  5. Lal, H., Cunningham, A. L., Godeaux, O., Chouchana, L., et al. (2015). Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine, 372(22), 2087-2096.
  6. GSK plc. (2024). Annual report 2023. London, United Kingdom: GSK plc.
  7. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. Silver Spring, MD: FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.